Please assess the completion status of the following clinical trial:

Trial Title: Preoperative Panitumumab and Radiotherapy in Rectal Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* ECOG Performance Status 0-1~* Histologically proven adenocarcinoma of the rectum, T3-T4 and/or N+ M0~* Wild-type KRAS~* No prior pelvic irradiation~* Normal bone marrow, hepatic, renal, cardiac functions~* No secondary malignancy~* No other active, uncontrolled disease~* Signed informed consent~Exclusion Criteria:~* KRAS mutation~* Established or suspected metastasis~* Prior pelvic irradiation~* Previous exposure to EGFR-targeting therapies~* Patients under any other investigational agent(s)~* Concurrent systemic immune therapy, chemotherapy, hormone therapy~* Drug and/or alcohol abuse~* Grade 3 to 4 allergic reaction to any of the components of the treatment~* History or presence of interstitial lung disease~* Active, uncontrolled cardiovascular disease

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- panitumumab (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).